✦ LIBER ✦

Tetrahydroaminoacridine and lecithin in the treatment of Alzheimer's disease

✍ Scribed by Henry C. Weinstein; Saskia Teunisse; Willem A. Gool

Publisher: Springer
Year: 1991
Tongue: English
Weight: 529 KB
Volume: 238
Category: Article
ISSN: 0340-5354
DOI: 10.1007/bf00319708

No coin nor oath required. For personal study only.

✦ Synopsis

In 12 ambulant patients with a clinical diagnosis of probable Alzheimer's disease, a 12-week, double-blind, placebo-controlled study with 100 mg/day tetrahydroaminoacridine (THA) and 10 g/day lecithin is reported. The aim of the study was to find whether treatment would result in an improvement of cognition, of functioning in daily life, decrease of behavioural disturbances, and decrease in burden experienced by the carers. Two of the six THA-treated patients demonstrated an increase on cognitive test scores with a moderate increase in the other outcome measurements. There was, however, no difference between the two groups in any outcome measurement after treatment. In addition, we found a reversible rise of liver transaminases in 4 of 6 patients in the treated group. This pilot study is too small to draw definite conclusions on the use of THA alone or in combination with lecithin. Our results suggest, however, that semi-structured interviews with the carers may be of value in the evaluation of treatment effects in patients with Alzheimer's disease.

📜 SIMILAR VOLUMES

Tetrahydroaminoacridine in Alzheimer's d

Tetrahydroaminoacridine in Alzheimer's disease

✍ B. Davies; D. Andrewes; R. Stargatt; D. Ames; V. Tuckwell; S. Davis 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 445 KB 👁 1 views

Tetrahydroaminoacridine (THA), a centrally acting anticholinesterase, was used in a two-month, double-blind, placebo-controlled crossover trial to treat 10 patients meeting DSM-111-R criteria for dementia of the Alzheimer type. Eight patients continued to take THA for a further three months. Nausea

The effect of tacrine and lecithin in Al

The effect of tacrine and lecithin in Alzheimer's disease

✍ K. Peace; N. H. G. Holford 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 602 KB

Tacrine, a cholinesterase inhibitor, has beneficial effects on cognition and global status in patients with Alzheimer's disease. These effects have been demonstrated in clinical trials by double-blind comparisons with placebo. Tacrine dosages have been studied in 5 protocols that used either enrichm

Effects of physostigmine and lecithin on

Effects of physostigmine and lecithin on memory in Alzheimer disease

✍ Dr. Bruce H. Peters; Harvey S. Levin 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 264 KB 👁 2 views

## Abstract Because there is evidence that central cholinergic mechanisms are depleted in dementia, we studied the effects of central cholinergic augmentation on the memory of 5 patients with Alzheimer disease. Patients received placebo, lecithin, physostigmine, or lecithin plus physostigmine in a

Immunological concept in the treatment o

Immunological concept in the treatment of Alzheimer's disease

✍ Beka Solomon 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 2 views

Advances in the drug treatment of Alzhei

Advances in the drug treatment of Alzheimer's Disease

✍ B. E. Leonard 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 2 views

There are two main approaches to the treatment of Alzheimer's disease. The ®rst approach is to prevent the neurodegenerative changes that ultimately cause irreversible damage to the brain. As the excessive formation of betaamyloid protein appears to play a primary role in the neurodegenerative proce

Long-term administration of oral physost

Long-term administration of oral physostigmine and lecithin improve memory in Alzheimer's disease

✍ Harvey S. Levin; Bruce H. Peters 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 2 views